Bladder & Urothelial Cancer Excellence Forum

Bladder & Urothelial Cancer

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Thomas Powles, MD, MBBS, Barts Cancer Institute

Videos

Enfortumab Vedotin and Pembrolizumab Among Patients With Advanced Urothelial Cancer in the First-Line Setting

04/11/2024

Featuring Thomas Powles, MBBS, MD

Featuring Thomas Powles, MBBS, MD ...

Thomas Powles, MBBS, MD, discusses results from the phase 3 EV-302 trial, which found enfortumab vedotin plus pembrolizumab improved survival outcomes among patients with previously untreated advanced urothelial carcinoma.

Thomas Powles, MBBS, MD,...

04/11/2024

Oncology

Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center

Podcasts

Sacituzumab Govitecan Plus Pembrolizumab in the TROPHY-U-01 Trial

03/07/2024

Featured Petros Grivas, MD, PhD

Featured Petros Grivas, MD, PhD ...

Petros Grivas, MD, PhD, shares results from the phase 2 TROPHY-U-01 study evaluating sacituzumab govetican plus pembrolizumab among patients with metastatic urothelial carcinoma following progression on platinum-chemotherapy.

Petros Grivas, MD, PhD, shares...

03/07/2024

Oncology

Andrea Apolo, MD, National Cancer Institute

Conference Coverage

Adjuvant Pembrolizumab New Therapeutic Option For High-Risk Muscle-Invasive Bladder Cancer

02/05/2024

Andrea Apolo , MD;

At the 2024 ASCO GU Cancers Symposium, Andrea Apolo, MD, shared insights from the phase 3 AMBASSADOR Alliance AO31501 study, looking at adjuvant pembrolizumab for patients with muscle-invasive bladder cancer at a high risk for recurrence.

At the 2024 ASCO GU Cancers...

02/05/2024

Oncology

Conference Coverage

HER2 and PD-L1 Immunohistochemistry Expression Among Patients With Advanced Bladder Cancer

01/30/2024

David Aggen , MD, PhD;

David Aggen, MD, shares insights from a retrospective analysis done to evaluate the association between HER2 mutation/amplification, HER2, and PD-L1 immunohistochemistry expression, and associations with clinical outcomes for advanced bladder...

David Aggen, MD, shares insights...

01/30/2024

Oncology

Conference Coverage

Enfortumab Vedotin Plus Pembrolizumab Potential New Standard of Care for Advanced Urothelial Carcinoma in the First-Line Setting

01/26/2024

Michiel van der Heijden , MD;

Michiel van der Heijden, MD, discusses the subgroup analyses of the phase 3 EV-302 study, evaluating enfortumab vedotin plus pembrolizumab among patients with locally advanced or metastatic urothelial carcinoma in the first-line setting.

Michiel van der Heijden, MD,...

01/26/2024

Oncology

Arlene Siefker-Radtke, MD, MD Anderson Cancer Center

Videos

Erdafitinib Shows Similar OS to Pembrolizumab Among Patients With FGFR-Altered Advanced/Metastatic Urothelial Carcinoma

11/16/2023

Arlene Seifker-Radtke , MD;

Arlene Siefker-Radtke, MD, discusses the THOR trial which found that erdafitinib had a similar OS to pembrolizumab among patients with advanced or metastatic urothelial carcinoma.

Arlene Siefker-Radtke, MD,...

11/16/2023

Oncology

Andrea Necchi, MD, San Raffaele Hospital

Videos

Intravesical Gemcitabine Delivery System, TAR-200, Shows Promise Among Patients With BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer

11/03/2023

Andrea Necchi , MD;

Andrea Necchi, MD, describes the results from cohort 2 of the SunRISe-1 trial, evaluating TAR-200 monotherapy among patients with high-risk, BCG-unresponsive non–muscle-invasive bladder cancer.

Andrea Necchi, MD, describes the...

11/03/2023

Oncology

Antoni Vilaseca, MD, Hospital Clínic de Barcelona

Videos

Novel Erdafitinib Intravesical Delivery System Showed Safety, Efficacy for Patients With Non–Muscle-Invasive Bladder Cancer With Select FGFR Alterations

11/01/2023

Antoni Vilaseca , MD;

Antoni Vilaseca, MD, discusses the novel erdafinitib delivery system for patients with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations.

Antoni Vilaseca, MD, discusses...

11/01/2023

Oncology

James Catto, MBChB, PhD, FRCS, University of Sheffield

Videos

Erdafitinib vs Intravesical Chemotherapy for High-Risk Non–Muscle-Invasive Bladder Cancer

10/23/2023

James Catto , MBChB, PhD, FRCS;

Prof James Catto, MBChB, PhD, FRCS, discusses the first randomized data from Cohort 1 of the THOR-2 trial investigating erdafitinib vs intravesical chemotherapy in high-risk FGFR-altered non–muscle-invasive bladder cancer whose disease...

Prof James Catto, MBChB, PhD,...

10/23/2023

Oncology

Videos

Assessment of Real World Avelumab Uptake for Patients with Urothelial Carcinoma

06/09/2023

At the 2023 ASCO Annual Meeting, Helen Moon, MD, discusses results from a study investigating the real world response rates of patients with urothelial carcinoma treated with first-line platinum-based chemotherapy, to assess the uptake of...

At the 2023 ASCO Annual Meeting,...

06/09/2023

Oncology

Recent News

News

Pembrolizumab Yields Meaningful Benefit in Advanced Urothelial Cancer

07/27/2020

Pembrolizumab was active in patients with advanced or metastatic cisplatin-ineligible urothelial carcinoma, according to long-term study findings.

Pembrolizumab was active in...

07/27/2020

Oncology

News

Switch Maintenance Pembrolizumab Improves Response, PFS in Metastatic Urothelial Cancer

05/01/2020

Switch maintenance pembrolizumab led to improved PFS and ORRs in patients with metastatic urothelial cancer, according to results from a phase 2 study.

Switch maintenance pembrolizumab...

05/01/2020

Oncology

News

Enfortumab Vedotin Monotherapy Yields Durable Responses in Metastatic Urothelial Cancer

02/26/2020

Enfortumab vedotin monotherapy has demonstrated meaningful and durable responses in patients with metastatic urothelial cancer.

Enfortumab vedotin monotherapy...

02/26/2020

Oncology

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology